Credit Suisse Group set a GBX 6,350 ($82.97) target price on AstraZeneca (LON:AZN) in a report issued on Friday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research firms have also issued reports on AZN. Shore Capital reiterated a hold rating on shares of AstraZeneca in a research note on Wednesday, August 15th. Liberum Capital reiterated a hold rating on shares of AstraZeneca in a research note on Monday, September 24th. HSBC set a GBX 4,840 ($63.24) price objective on shares of AstraZeneca and gave the company a sell rating in a research note on Wednesday, August 15th. Barclays reiterated an overweight rating on shares of AstraZeneca in a research note on Monday, September 24th. Finally, UBS Group reiterated a neutral rating and set a GBX 5,900 ($77.09) price objective on shares of AstraZeneca in a research note on Tuesday, September 25th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company. AstraZeneca currently has a consensus rating of Hold and an average price target of GBX 5,927.44 ($77.45).

LON AZN traded down GBX 28 ($0.37) during mid-day trading on Friday, hitting GBX 5,927 ($77.45). The company’s stock had a trading volume of 2,638,281 shares, compared to its average volume of 2,310,000. AstraZeneca has a 52-week low of GBX 4,260 ($55.66) and a 52-week high of GBX 5,520 ($72.13).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Further Reading: What is a Derivative?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.